Boston Scientific (BSX) Cash & Equivalents (2009 - 2026)

Boston Scientific has disclosed Cash & Equivalents across 18 years of filings, most recently posting $539.0 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 0.94% year-over-year to $539.0 million; the TTM figure through Jun 2026 stood at $539.0 million (up 0.94% YoY), while the FY2025 annual figure was $2.0 billion, up 224.26% from the prior year.
• Cash & Equivalents came in at $539.0 million for Q2 2026 at Boston Scientific, down from $1.5 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $2.9 billion in Q2 2024 to a low of $276.0 million in Q2 2022.
• Average Cash & Equivalents over 5 years is $1.1 billion, with a median of $795.0 million recorded in 2023.
• Year-over-year, Cash & Equivalents slumped 89.68% in 2022 and surged 583.8% in 2024.
• Over 5 years, Cash & Equivalents stood at $928.0 million in 2022, then decreased by 6.79% to $865.0 million in 2023, then decreased by 29.94% to $606.0 million in 2024, then surged by 224.26% to $2.0 billion in 2025, then sank by 72.57% to $539.0 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $539.0 million in Q2 2026, $1.5 billion in Q1 2026, and $2.0 billion in Q4 2025.